PolyPid’s D-PLEX100 May Have Way Forward Despite Phase III Miss

The SHIELD I trial, for preventing surgical site infections, did not meet its primary and key secondary endpoints, but a subgroup analysis did, while COVID-19 may have muddled results.

PolyPid announced results from the Phase III study of D-PLEX100 in preventing surgical site infections • Source: Shutterstock

PolyPid Ltd.’s Phase III SHIELD I trial of D-PLEX100 for preventing surgical site infections (SSIs) among patients receiving abdominal surgery failed to be the successful trial that analysts had thought it would be. However, better-than-expected performance in the control arm due to COVID-19 restrictions appears to have played a role, and the trial did meet its primary endpoint in a subgroup analysis, meaning the drug may have a future yet.

The Israeli biotech announced topline results from the 977-patient study on 2 September, showing that in the intent-to-treat (ITT) analysis, it did not meet its primary endpoint of showing a statistically significant decrease in SSIs and mortality for patients receiving D-PLEX100 plus standard-of-care treatment versus the standard of care alone

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By 

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By 

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

 

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

More from R&D

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By 

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.